about
Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysisOverexpression of the polycythemia rubra vera-1 gene in essential thrombocythemiaLeukocytosis as a major thrombotic risk factor in patients with polycythemia veraThe G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study.Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.Venous thromboembolism in multiple myeloma.Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.Fondaparinux in pregnancy: Could it be a safe option? A review of the literature.Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies.Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis of observational studies.Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis.Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies.Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyCauses of adult splanchnic vein thrombosis in the mediterranean area.Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia.Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controlsSplanchnic vein thrombosis: clinical presentation, risk factors and treatment.Abdominal thromboses of splanchnic, renal and ovarian veins.Extra-abdominal venous thromboses at unusual sites.Are MPNs vascular diseases?Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.Inherited risk factors for venous thromboembolism.Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis.Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience.Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry.Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease.Safety of granulocyte-colony-stimulating factor in acute myocardial infarction (the Rigenera study).The interaction between small intestinal bacterial overgrowth and warfarin treatment.Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia.Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants.Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease.Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
P50
Q28082873-FBD9EFB2-E422-47D6-87A0-8B87FE6A50C5Q28207385-FD839D9A-4BE0-4A8F-9F76-22283257886BQ28210331-03E5DB6C-96BE-4FEB-95A2-98A690B98FCFQ33303765-E81C9E1B-B93D-48E4-BB3C-3D2B3F811745Q33387332-B89BFBAC-5FCD-4D3A-A728-538989EDFC56Q33388109-0AC19305-40A7-4435-B841-2140403805D0Q33413686-00324876-1CE1-4D49-84C5-A693808815C3Q33415996-12314B55-3735-4067-BE90-BE6413271C12Q33422323-29BF4246-3C89-44E5-A8AC-1D81373849CDQ34502105-2E6DAF81-A06B-47D1-92FB-1F2BD2DC6B99Q35158686-61B8E359-CBA0-4063-A7C9-FE3C27C9197DQ35162504-D2D04C6B-113C-405D-934D-A4A99F6BAC04Q35539424-06F99F3F-4F3C-4AC6-861C-F66DA912D262Q35636700-1314C5C0-6AFA-4A06-982E-76B7D1EA0104Q35640769-15C57D36-BF16-43EC-B1FE-8FF78765AD2AQ35867315-6BCD27BB-D778-4867-A4E0-1039B60B518CQ35886257-3F509849-6092-4C4A-AFD2-095CA762ECE6Q35950753-D5C9CDCD-BF1E-40F8-8C25-E48C1B66D056Q36685162-4EB9C3DD-A104-4F41-BF62-4893090FE558Q37175624-2C54FBF5-8469-49B1-B0C6-3C0AC350D7DFQ37578073-C4219FEA-10DE-4872-A26D-5A1B86C96D4AQ37604068-0C3E24A8-D7EA-4420-B336-CBA12719C7F7Q37763593-337834AF-44B8-4E34-9D5D-15296D185306Q38041793-6A152A81-E04A-40A5-90CE-B230FE178D9BQ38041794-3AB6BA30-6A9A-4CF4-B40E-2D8F9BF46DC6Q38137750-DBB566F2-8FEE-475D-A986-27DA8FD5D5D7Q38174710-29D08832-7972-4EBB-95CC-6697B918FE96Q38178063-D27A5DA6-D816-4232-A2A7-ABCC5CC4AE5AQ39210015-3261CE53-6675-4A26-BC0A-E4245E99A5D0Q39270841-6ADE65F1-AF3F-4DF6-AD7E-21C9F49184DCQ39542698-A968DB87-96E0-4849-982F-20CD95B850CDQ40291287-53EEB60E-B041-4CF7-9C25-846000073F76Q40744463-059A11C2-6402-43A0-9E92-6702C704B777Q41754449-8934410D-056E-47D0-BDA1-6B61D009315DQ42829579-9FDE9E8C-F7C1-4D06-9F66-EF49FA66765DQ43281710-BAB66A51-4120-409C-8FF8-6929AC420DD3Q43621401-537FF8C2-3698-40DB-892D-19CE7E912FECQ43716343-D565AEB9-F1AB-4619-8CAB-6CF9210F9B81Q43757657-55D6D26F-C279-4B5B-A1E1-50BA3AF23FFFQ43922582-200F7CD7-7EE7-46B9-868C-45571F30C666
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Valerio De Stefano
@ast
Valerio De Stefano
@en
Valerio De Stefano
@es
Valerio De Stefano
@nl
Valerio De Stefano
@sl
type
label
Valerio De Stefano
@ast
Valerio De Stefano
@en
Valerio De Stefano
@es
Valerio De Stefano
@nl
Valerio De Stefano
@sl
prefLabel
Valerio De Stefano
@ast
Valerio De Stefano
@en
Valerio De Stefano
@es
Valerio De Stefano
@nl
Valerio De Stefano
@sl
P1053
J-3650-2018
P106
P1153
7006192748
P21
P31
P3829
P496
0000-0002-5178-5827